20,000 children die yearly from injuries, with 40 admitted and 1,120 treated in ERs for each death. 50,000 survivors suffer permanent disabilities. Head injuries cost over $5 billion annually in the US from treatment, lost productivity, and other costs. Management of pediatric head trauma requires stabilizing the airway and spine, restoring circulation, diagnostic testing, and monitoring for increased intracranial pressure, with aggressive treatment in the ICU if consciousness is altered. Preventing head injuries through public health measures could reduce these substantial costs and disabilities.
Consultant in Genreral Paediatrics at St Mary's Hospital, Padding, London talks at Meningitis Research Foundation's Pushing the Boundaries: Life beyond limb loss day in October 2014
CRISPR-Cas9, a revolutionary gene-editing tool, holds immense potential to reshape medicine, agriculture, and our understanding of life. But like any powerful tool, it comes with ethical considerations.
Unveiling CRISPR: This naturally occurring bacterial defense system (crRNA & Cas9 protein) fights viruses. Scientists repurposed it for precise gene editing (correction, deletion, insertion) by targeting specific DNA sequences.
The Promise: CRISPR offers exciting possibilities:
Gene Therapy: Correcting genetic diseases like cystic fibrosis.
Agriculture: Engineering crops resistant to pests and harsh environments.
Research: Studying gene function to unlock new knowledge.
The Peril: Ethical concerns demand attention:
Off-target Effects: Unintended DNA edits can have unforeseen consequences.
Eugenics: Misusing CRISPR for designer babies raises social and ethical questions.
Equity: High costs could limit access to this potentially life-saving technology.
The Path Forward: Responsible development is crucial:
International Collaboration: Clear guidelines are needed for research and human trials.
Public Education: Open discussions ensure informed decisions about CRISPR.
Prioritize Safety and Ethics: Safety and ethical principles must be paramount.
CRISPR offers a powerful tool for a better future, but responsible development and addressing ethical concerns are essential. By prioritizing safety, fostering open dialogue, and ensuring equitable access, we can harness CRISPR's power for the benefit of all. (2998 characters)
India Clinical Trials Market: Industry Size and Growth Trends [2030] Analyzed...Kumar Satyam
According to TechSci Research report, "India Clinical Trials Market- By Region, Competition, Forecast & Opportunities, 2030F," the India Clinical Trials Market was valued at USD 2.05 billion in 2024 and is projected to grow at a compound annual growth rate (CAGR) of 8.64% through 2030. The market is driven by a variety of factors, making India an attractive destination for pharmaceutical companies and researchers. India's vast and diverse patient population, cost-effective operational environment, and a large pool of skilled medical professionals contribute significantly to the market's growth. Additionally, increasing government support in streamlining regulations and the growing prevalence of lifestyle diseases further propel the clinical trials market.
Growing Prevalence of Lifestyle Diseases
The rising incidence of lifestyle diseases such as diabetes, cardiovascular diseases, and cancer is a major trend driving the clinical trials market in India. These conditions necessitate the development and testing of new treatment methods, creating a robust demand for clinical trials. The increasing burden of these diseases highlights the need for innovative therapies and underscores the importance of India as a key player in global clinical research.
More Related Content
Similar to Head truma in children Prof Azza Darwish presntation
Consultant in Genreral Paediatrics at St Mary's Hospital, Padding, London talks at Meningitis Research Foundation's Pushing the Boundaries: Life beyond limb loss day in October 2014
CRISPR-Cas9, a revolutionary gene-editing tool, holds immense potential to reshape medicine, agriculture, and our understanding of life. But like any powerful tool, it comes with ethical considerations.
Unveiling CRISPR: This naturally occurring bacterial defense system (crRNA & Cas9 protein) fights viruses. Scientists repurposed it for precise gene editing (correction, deletion, insertion) by targeting specific DNA sequences.
The Promise: CRISPR offers exciting possibilities:
Gene Therapy: Correcting genetic diseases like cystic fibrosis.
Agriculture: Engineering crops resistant to pests and harsh environments.
Research: Studying gene function to unlock new knowledge.
The Peril: Ethical concerns demand attention:
Off-target Effects: Unintended DNA edits can have unforeseen consequences.
Eugenics: Misusing CRISPR for designer babies raises social and ethical questions.
Equity: High costs could limit access to this potentially life-saving technology.
The Path Forward: Responsible development is crucial:
International Collaboration: Clear guidelines are needed for research and human trials.
Public Education: Open discussions ensure informed decisions about CRISPR.
Prioritize Safety and Ethics: Safety and ethical principles must be paramount.
CRISPR offers a powerful tool for a better future, but responsible development and addressing ethical concerns are essential. By prioritizing safety, fostering open dialogue, and ensuring equitable access, we can harness CRISPR's power for the benefit of all. (2998 characters)
India Clinical Trials Market: Industry Size and Growth Trends [2030] Analyzed...Kumar Satyam
According to TechSci Research report, "India Clinical Trials Market- By Region, Competition, Forecast & Opportunities, 2030F," the India Clinical Trials Market was valued at USD 2.05 billion in 2024 and is projected to grow at a compound annual growth rate (CAGR) of 8.64% through 2030. The market is driven by a variety of factors, making India an attractive destination for pharmaceutical companies and researchers. India's vast and diverse patient population, cost-effective operational environment, and a large pool of skilled medical professionals contribute significantly to the market's growth. Additionally, increasing government support in streamlining regulations and the growing prevalence of lifestyle diseases further propel the clinical trials market.
Growing Prevalence of Lifestyle Diseases
The rising incidence of lifestyle diseases such as diabetes, cardiovascular diseases, and cancer is a major trend driving the clinical trials market in India. These conditions necessitate the development and testing of new treatment methods, creating a robust demand for clinical trials. The increasing burden of these diseases highlights the need for innovative therapies and underscores the importance of India as a key player in global clinical research.
Antibiotic Stewardship by Anushri Srivastava.pptxAnushriSrivastav
Stewardship is the act of taking good care of something.
Antimicrobial stewardship is a coordinated program that promotes the appropriate use of antimicrobials (including antibiotics), improves patient outcomes, reduces microbial resistance, and decreases the spread of infections caused by multidrug-resistant organisms.
WHO launched the Global Antimicrobial Resistance and Use Surveillance System (GLASS) in 2015 to fill knowledge gaps and inform strategies at all levels.
ACCORDING TO apic.org,
Antimicrobial stewardship is a coordinated program that promotes the appropriate use of antimicrobials (including antibiotics), improves patient outcomes, reduces microbial resistance, and decreases the spread of infections caused by multidrug-resistant organisms.
ACCORDING TO pewtrusts.org,
Antibiotic stewardship refers to efforts in doctors’ offices, hospitals, long term care facilities, and other health care settings to ensure that antibiotics are used only when necessary and appropriate
According to WHO,
Antimicrobial stewardship is a systematic approach to educate and support health care professionals to follow evidence-based guidelines for prescribing and administering antimicrobials
In 1996, John McGowan and Dale Gerding first applied the term antimicrobial stewardship, where they suggested a causal association between antimicrobial agent use and resistance. They also focused on the urgency of large-scale controlled trials of antimicrobial-use regulation employing sophisticated epidemiologic methods, molecular typing, and precise resistance mechanism analysis.
Antimicrobial Stewardship(AMS) refers to the optimal selection, dosing, and duration of antimicrobial treatment resulting in the best clinical outcome with minimal side effects to the patients and minimal impact on subsequent resistance.
According to the 2019 report, in the US, more than 2.8 million antibiotic-resistant infections occur each year, and more than 35000 people die. In addition to this, it also mentioned that 223,900 cases of Clostridoides difficile occurred in 2017, of which 12800 people died. The report did not include viruses or parasites
VISION
Being proactive
Supporting optimal animal and human health
Exploring ways to reduce overall use of antimicrobials
Using the drugs that prevent and treat disease by killing microscopic organisms in a responsible way
GOAL
to prevent the generation and spread of antimicrobial resistance (AMR). Doing so will preserve the effectiveness of these drugs in animals and humans for years to come.
being to preserve human and animal health and the effectiveness of antimicrobial medications.
to implement a multidisciplinary approach in assembling a stewardship team to include an infectious disease physician, a clinical pharmacist with infectious diseases training, infection preventionist, and a close collaboration with the staff in the clinical microbiology laboratory
to prevent antimicrobial overuse, misuse and abuse.
to minimize the developme
The dimensions of healthcare quality refer to various attributes or aspects that define the standard of healthcare services. These dimensions are used to evaluate, measure, and improve the quality of care provided to patients. A comprehensive understanding of these dimensions ensures that healthcare systems can address various aspects of patient care effectively and holistically. Dimensions of Healthcare Quality and Performance of care include the following; Appropriateness, Availability, Competence, Continuity, Effectiveness, Efficiency, Efficacy, Prevention, Respect and Care, Safety as well as Timeliness.
Deep Leg Vein Thrombosis (DVT): Meaning, Causes, Symptoms, Treatment, and Mor...The Lifesciences Magazine
Deep Leg Vein Thrombosis occurs when a blood clot forms in one or more of the deep veins in the legs. These clots can impede blood flow, leading to severe complications.
ICH Guidelines for Pharmacovigilance.pdfNEHA GUPTA
The "ICH Guidelines for Pharmacovigilance" PDF provides a comprehensive overview of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) guidelines related to pharmacovigilance. These guidelines aim to ensure that drugs are safe and effective for patients by monitoring and assessing adverse effects, ensuring proper reporting systems, and improving risk management practices. The document is essential for professionals in the pharmaceutical industry, regulatory authorities, and healthcare providers, offering detailed procedures and standards for pharmacovigilance activities to enhance drug safety and protect public health.
Global launch of the Healthy Ageing and Prevention Index 2nd wave – alongside...ILC- UK
The Healthy Ageing and Prevention Index is an online tool created by ILC that ranks countries on six metrics including, life span, health span, work span, income, environmental performance, and happiness. The Index helps us understand how well countries have adapted to longevity and inform decision makers on what must be done to maximise the economic benefits that comes with living well for longer.
Alongside the 77th World Health Assembly in Geneva on 28 May 2024, we launched the second version of our Index, allowing us to track progress and give new insights into what needs to be done to keep populations healthier for longer.
The speakers included:
Professor Orazio Schillaci, Minister of Health, Italy
Dr Hans Groth, Chairman of the Board, World Demographic & Ageing Forum
Professor Ilona Kickbusch, Founder and Chair, Global Health Centre, Geneva Graduate Institute and co-chair, World Health Summit Council
Dr Natasha Azzopardi Muscat, Director, Country Health Policies and Systems Division, World Health Organisation EURO
Dr Marta Lomazzi, Executive Manager, World Federation of Public Health Associations
Dr Shyam Bishen, Head, Centre for Health and Healthcare and Member of the Executive Committee, World Economic Forum
Dr Karin Tegmark Wisell, Director General, Public Health Agency of Sweden
R3 Stem Cells and Kidney Repair A New Horizon in Nephrology.pptxR3 Stem Cell
R3 Stem Cells and Kidney Repair: A New Horizon in Nephrology" explores groundbreaking advancements in the use of R3 stem cells for kidney disease treatment. This insightful piece delves into the potential of these cells to regenerate damaged kidney tissue, offering new hope for patients and reshaping the future of nephrology.
Leading the Way in Nephrology: Dr. David Greene's Work with Stem Cells for Ki...Dr. David Greene Arizona
As we watch Dr. Greene's continued efforts and research in Arizona, it's clear that stem cell therapy holds a promising key to unlocking new doors in the treatment of kidney disease. With each study and trial, we step closer to a world where kidney disease is no longer a life sentence but a treatable condition, thanks to pioneers like Dr. David Greene.
Leading the Way in Nephrology: Dr. David Greene's Work with Stem Cells for Ki...
Head truma in children Prof Azza Darwish presntation
1.
2.
3.
4. 20.000 child yearly
Die due to Injury
For each
child dies
Additional 40 are admitted
1120 are treated in ER
& released home
Fifty thousand
of these surviving children
will suffer
permanent disability
5. 1.6 million
head injuries
every year
In USA
> 250.000
Admitted to
Hospital
60.000
Deaths
70.000 –
90.000
Permanent
Neurological
6. In USA
According to the national head and
spinal cord survey in USA, direct costs of
diagnosis, treatment and rehabilitation and
the direct costs of society from lost
productivity, total more than five billion
dollars. This doesn’t include such
psychological and emotional issues as pain,
suffering, effect on family and significant
others or disability. Therefore, the total
costs are probably enormous.
7. 121 Deaths of
Motor Vehicle at 5
years or more
In Egypt
334 Deaths of
Motor Vehicle
at 10 years or
more
10% of orthopedic
patients (5-15 yrs)
hospitalized due to
trauma
1998
2000
10. Common Causes
of Head Injury
Motor Vehicle
Personal Fighting
Riding Bicycle
In Late
Childhood
Falls
11. Unique Pediatric Parameters and significance
to trauma Care:
Variable Significant
Cerebral edema developsrapidly
Large volume of blood in head
Flexion/extension injuries occur
Poor muscular support in neck
Higher center of gravity
Increased head to body ratio
12. Unique Pediatric Parameters and significance
to trauma Care:
Variable Significant
Increasethe risk of brain injury
Thinner cranial bones.
Fractures are common
Bones are soft and pliable
14. Signs & Symptoms:
Amnesia about event
Nausea
Vomiting
Headache
Conscious
Loss consciousness
(5-10 min)
Mild
Moderate
Unconsciousness
more than 10 min
Signs of Increased ICP
Altered Vital Signs
Severe
15. Assessment of
Head Injured Patient
Primary
Trauma
Survey
A
Airway
Stabilized Cervical
Spine
B Breathing
C Circulation
D Disability
(LOC, Pupils)
16. Assessment of
Head Injured Patient
Secondary
Trauma
Survey
Glascow
Coma
Scale
Glascow
Coma
Scale
Eye Opening
Verbal Response
Motor Response
4 Spontaneously
3 To Speech
2 To Pain
1 None
5 Orientation
4 Sentences
3 Words
2 Sounds
1 None
6 Obeys
Commands
5 Localizing
4 Normal
Flexion
3 Abnormal
Flexion
2 Extension
1 None
17.
18. Management of Head Trauma
Prehospital
Phase
Initial
Hospital
Management
Continuing
Management
In
ICU
19. Prehospital Phase:
Goals
Maintain a Patent Airway
Fluid Resuscitation
Immobilize the Cervical
Region
Assess the Level of
consciousness
Maintain adequate BP
20. History – Taking in Head Injury
Mechanism of injury
Time elapsed
Period of loss consciousness
Any pre / post – traumatic amnesia
Condition since injury , such as nausea,
vomiting, confusion, visual disturbance,
lethargy or dizziness
21. Indications for Hospital Admission
Decreased consciousness
Neurological deficit
Severe headache and persistent
vomiting
Confusion
22. Initial Hospital Management:
Give Oxygen Concentration
100%
Restore Blood Pressure
& Normal Circulation
Diagnostic Studies
Diagnostic Studies
Physical
Examination C.T.
X Ray
MRI
Neurological
Assessment
S&S of ICP
24. Head Injury Advice Sheet
Observing a patient every 2
hours
Ensure he wakes easily and is
orientated when awake .
Ensure the patient is able to
move all limbs
25. Head Injury Advice Sheet
You should return to hospital if any of the
following occur:
Confusion, excessive sleeping; difficulty
in rowzing patient
Severe headache, double vision
Limb weakness, convulsions or “passing
out”
Discharge of blood/ fluid from nose / ears
28. Continuous Management in ICU:
Endotracheal Suction
Care of Fever
Prevention of Jugular Venous
Outflow Obstruction
Change Position
Seizure prophylaxis
29. Continuous Management in ICU:
Management of Established
Intracranial Hypertension
Elevation of the
Head of Bed
to 30
)
Monitor ICP
Use Hyperosmotic
Agent
30. Keep the head and
neck in neutral
alignment.
•Head flexion, extension or rotation.
•Lateral neck flexion.
•Pushing up the patient in bed.
•Extreme hip flexion.
Avoid
Careful monitoring
of appropriate
physiologic
variables.
34. Disabled children should be adapted to
life by facilitating the process of
rehabilitation planning through
appropriate resource programs.
Management of children with severe
head injury is complex and requires a
coordinated, comprehensive ,and
multidisciplinary approach.
Considering the enormous costs to
society , we need to invest greater
resources in the prevention of this
pandemic